Rationale: Glutamate is a major signaling molecule that binds to glutamate receptors including the ionotropic glutamate receptors; kainate (KA) receptor (KAR), the N-methyl-D-aspartate receptor, and the ␣-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor. Each is well characterized in the central nervous system, but glutamate has important signaling roles in peripheral tissues as well, including a role in regulating platelet function. Objective: Our previous work has demonstrated that glutamate is released by platelets in high concentrations within a developing thrombus and increases platelet activation and thrombosis. We now show that platelets express a functional KAR that drives increased agonist induced platelet activation. Methods and Results: KAR induced increase in platelet activation is in part the result of activation of platelet cyclooxygenase in a mitogen-activated protein kinase-dependent manner. Platelets derived from KAR subunit knockout mice (GluR6 ؊/؊ ) are resistant to KA effects and have a prolonged time to thrombosis in vivo. Importantly, we have also identified polymorphisms in KAR subunits that are associated with phenotypic changes in platelet function in a large group of whites and blacks. Conclusions: Our data demonstrate that glutamate regulation of platelet activation is in part cyclooxygenasedependent and suggest that the KAR is a novel antithrombotic target. (Circ Res. 2009;105:595-603.) 
T hrombosis is driven by complex interactions between platelets, endothelial cells, and coagulation factors. Initial platelet activating events trigger intracellular signaling pathways necessary for rapid and efficient thrombus formation. These include changes in intracellular ion concentrations and pH, conformational changes in receptors such as Glycoprotein IIb/IIIa (GPIIb/IIIa), granule exocytosis, and secretion of vasoactive mediators. Many granule constituents are shared between platelets and neurons including Substance P, ADP, ATP, serotonin, and glutamate. [1] [2] [3] Glutamate signaling is well explored in the brain, but glutamate effects on platelet function are less well studied and only beginning to be understood.
Ionotropic glutamate receptors are classified as kainate (KA) receptors (KAR), N-methyl-D-aspartate (NMDA) receptors (NMDAR), and ␣-amino-3-hydroxy-5-methyl-4isoxazolepropionic acid (AMPA) receptors (AMPAR) based on their sensitivity to the ligand they are named for.
NMDARs mediate the influx of calcium, whereas AMPAR and KAR primarily mediate sodium influx on ligand binding. AMPAR and KAR are closely related in their tetrameric structure (4 subunits) but comprise distinct receptor subunits. KainateR subunits are commonly designated as GluR5, GluR6, GluR7, KA1, and KA2 (genes are also designated GRIK1 through 5, respectively), 4 and each subunit type is the product of a distinct gene. The KAR was identified by its activation in response to the naturally occurring marine toxin kainic acid and has similar activity to AMPAR but is less well studied. GluR5-7 can form homomers (example, all GluR5) and heteromers (example, a receptor composed of both GluR5 and GluR6). KA1 and KA2 can only be part of functional receptors by combining with one of the GluR5-7 subunits. 5, 6 Like AMPAR, when activated the KAR allows sodium influx at a rate similar to that of the AMPAR, but KARs desensitize more rapidly after ligand binding. Glutamate receptors are best described in the central nervous system, but are also expressed and functional in many tissues outside of the central nervous system. 7 For example, AMPA can stimulate insulin release from ␤-cells in the pancreas, and the AMPAR subunit GluR3 has been described on circulating T-lymphocytes where it has a potential role in T-cell chemotaxis and adhesion. 8 Other glutamate receptors, such as the NMDAR, have been described in osteoblasts, osteoclasts, and megakaryocytes. 7, 9 Most peripheral glutamate receptors when cloned and sequenced are identical to those of the central nervous system. 7 We have previously demonstrated using a real-time glutamate sensitive enzymatic probe that glutamate reaches very high concentrations (greater than 400 mol/L) within a developing thrombus. 1 We have also demonstrated that glutamate signaling has an important role in efficient thrombus formation by amplifying platelet activation, in part through platelet expressed AMPARs. 1 Glutamate signaling induces mitogen activated protein kinase (MAPK) signaling pathways in neurons. 10 MAPK messengers, including p38, are well described platelet signaling molecules. [11] [12] [13] MAPK p38 is phosphorylated in agoniststimulated platelets and dominant negative MAPK signaling inhibition reduces functional outcomes of agonist stimulation, such as GPIIb/IIIa activation. 13 Platelet cyclooxygenase (COX) activation has been demonstrated to be downstream of MAPK in response to receptor stimulation. 13, 14 COX activation and the production of prostaglandins (such as thromboxane), is an important step in efficient thrombus generation. [15] [16] [17] Kainate-induced seizures drive neuronal COX stimulation 18 -20 and KAR signaling can induce activation of MAPK pathways in neurons, including p38 pathways. 21, 22 This provides a background for a possible role of KAR signaling through MAPK pathways in platelet COX activation.
We now demonstrate that glutamate signaling through the Kainate type of glutamate receptor is also an important regulator of platelet function, in part by stimulating cyclooxygenase, and that this effect is dependent on MAPK signaling pathways. We also demonstrate that platelets from mice lacking KAR subunits do not respond to KA and that these mice have prolonged time to thrombosis in vivo. Furthermore, we have identified polymorphisms in the KAR that results in platelet functional changes in human populations.
Methods
GluR6 Ϫ/Ϫ mice are on a mixed 129 and C57Bl6/J background. Littermate wild-type mice were used as controls. For thromboxane production studies platelet-rich plasma (PRP) was pretreated with inhibitors for at least 20 minutes before stimulation. Platelets were pelleted after treating with indomethacin (20 mol/L, Sigma). Plasma was isolated for the TxB 2 ELISA and the platelet pellet lysed in p38 ELISA lysis buffer for measurement of P-p38. Plasma was further purified using a C-18 SPE cartridge (Amersham). All other materials and studies are completely described in the supplemental materials (available online at http://circres.ahajournals.org).
Results

KAR Signaling Increases Platelet Activation
Our previous studies demonstrated that glutamate pretreatment increased agonist-induced platelet activation. 1 Glutamate by itself does not directly alter the expression of surface markers of platelet activation, such as GPIIb/IIIa activation (PAC-1 antibody binding) and P-selectin expression. 1 However, as shown in Figure 1A , pretreatment of platelets with glutamate before agonist stimulation, such as with the thromboxane receptor agonist U46619 (1 mol/L), greatly increased platelet activation as determined by increase in PAC-1 antibody binding ( Figure 1A ; MFI indicates mean fluorescent intensity). Our previous work has also shown that glutamate effects are in part mediated by AMPAR. 1 The NMDAR has also been described on platelets, but pretreatment of platelets with NMDA does not increase agonist induced platelet activation (supplemental Figure I) . The other class of glutamate receptor that is similar in structure and function to AMPAR is KAR. To begin to explore the role of KAR in platelet activation, platelets were incubated with KA (250 mol/L) before platelet activation with U46619 (1 mol/L). Like glutamate, KA alone has no effect on PAC-1 antibody binding ( Figure 1B , white bars). However, KA pretreatment increased platelet activation approximately 3 times that of control treated platelets ( Figure  1B , black bars). A KA dose response curve was performed and as little as 100 mol/L of KA significantly increased platelet activation ( Figure 1C ). These are physiologically relevant glutamate and KA concentrations, as we have shown in the past that the concentration of glutamate in a developing thrombus is greater than 400 mol/L. 1 KARs are made of subunits that assemble to form a tetrameric receptor complex. To demonstrate that platelets express KAR subunits, human platelets and mouse brain lysates were immunoblotted. Platelets express both GluR5 and GluR6 protein (Figure 2A , top). In addition, mRNA was isolated from rat primary neurons and the megakaryocyte cell line MEG-01, and RT-PCR was performed with primers specific for GluR5 and GluR6. MEG-01 cells also express GluR5 and GluR6 mRNA (Figure 2A , bottom).
Non-standard Abbreviations and Acronyms
Kainate, particularly at higher concentrations, can have some AMPAR affinity, although it is much less than its KAR affinity. To demonstrate that the KA induced increase in platelet activation was specific to KAR, we used both pharmacological and genetic methods. ATPA is an agonist that only acts on GluR5-containing receptors. At 100 mol/L ATPA nearly doubled TRAP induced platelet activation, and as little as 10 mol/L also significantly increased PAC-1 binding ( Figure 2B , lower concentrations had no effect, not shown). To confirm KA-induced effects are mediated by KAR signaling, platelets were isolated from GluR6 Ϫ/Ϫ mice and littermate control wild-type (WT) mice, incubated with control buffer or KA (250 mol/L), and then activated with thrombin (0.1 U/mL). WT and GluR6 Ϫ/Ϫ platelets have similar thrombin responses (supplemental Figure II) . KA pretreatment nearly doubled WT platelet activation, but had no effect on GluR6 Ϫ/Ϫ platelets as measured by GPIIb/IIIa activation using JON/A antibody binding ( Figure 2C ).
To further demonstrate that KAR has an important role in platelet activation we performed platelet aggregation studies in the presence of control buffer (PBS) or the KAR antagonist UBP302. PRP was incubated with UBP302 (50 mol/L) for 
KAR Signaling Increases Platelet COX Activation
Kainate induced seizures and neuronal loss are in part attributable to induction and expression of cyclooxygenases COX-1 and COX-2. 20 Platelets primarily express COX-1 under normal physiological conditions, but COX-2 expression can be induced in pathophysiologic processes. 23 We determined whether or not KAR signaling in platelets stimulated COX. We first incubated platelets with the endogenous ligand for KAR, glutamate, to see whether this led to the production and release of thromboxane from platelets. Human PRP (approximately 1ϫ10 8 total platelets per reaction) were treated with control buffer, glutamate alone, or glutamate in the presence of the COX inhibitor indomethacin (20 mol/L) as a negative control. Platelets were also stimulated with low dose TRAP (0.5 mol/L) as a positive control. After 10 minutes platelets were pelleted in the presence of 20 mol/L of indomethacin to block any further COX activation. Thromboxane (Tbx) release into the supernatant was determined using an EIA that measures the stable TxA2 breakdown product, TxB2 (plasma was first purified by column purification prior to concentration determination to increase EIA TxB2 specificity). Glutamate induced platelet thromboxane production, and this was completely blocked by indomethacin pretreatment ( Figure 3A) . Similar results were also found when washed platelets were used instead of PRP (supplemental Figure III) . To determine whether glutamate induced thromboxane production may in part be attributable to signaling through the KAR, platelets were incubated with control buffer (PBS), KA (250 mol/L), or KA after treatment with the KAR antagonist UBP301 (200 mol/L). Similar to glutamate, KA increased TxB2 production ( Figure  3B , white versus black bars) and receptor antagonism inhibited KA induced increase in TxB2 ( Figure 3B , black versus gray bars). COX activation was confirmed by measuring PGE2 production (supplemental Figure IV) and AMPAR signaling also has a similar effect on thromboxane production (supplemental Figure V) . Glutamate stimulation of thromboxane production may in part account for the "priming" effect of glutamate receptor signaling that drives an increase in platelet activation in response to agonist stimulation.
We also determined the kinetics of KA-induced TbxB2 production by incubating platelets with PBS or KA and measuring TbxB2 after 5, 10, 20, and 30 minutes. At 5 minutes post KA there was no change in TbxB2, but after 10 minutes a significant increase in TbxB2 was found ( Figure  3C ). There was an additional increase noted after 20 and 30 minutes, but the greatest increase was seen between 5 and 10 minutes post KA ( Figure 3C ).
To confirm these pharmacological data we used platelets isolated from WT and GluR6 Ϫ/Ϫ mice. Using methods similar to the human platelet studies, washed WT and GluR6 Ϫ/Ϫ platelets were incubated with PBS or KA (250 mol/L) and TxB2 measured by EIA. KA increased WT mouse thromboxane production ( Figure 3D , left side) but had no effect on thromboxane production from GluR6 Ϫ/Ϫ platelets ( Figure 3D, right side) . This provides complementary genetic evidence that KA induced COX activation is through the KAR.
KAR Signaling Activates COX in a MAPK Dependent Manner
MAPK signaling has been implicated as a pathway leading to COX activation in many cell types, including renal glomeruli, neurons, and platelets. 13, 14, 22, 24, 25 KAR signaling is also known to activate MAPK pathways in neurons. 22 We therefore explored whether KAR signaling drives thromboxane production in a MAPK dependent manner.
The MAPK p38 pathway is induced in response to numerous platelet agonists including vWF, collagen, and thrombin, 14, 24 and mice lacking p38 have prolonged time to thrombus formation. 26 We determined whether KAR signaling activates platelet p38 MAPK pathway by incubating platelets with PBS, KA (250 mol/L), or KA after the KAR specific antagonist UBP302. TRAP stimulation (0.5 mol/L) was used as a positive control. p38 phosphorylation (P-p38) was quantified by ELISA. KA treatment increased P-p38 approximately twice that of resting platelet levels and this was blocked by KAR antagonism ( Figure 4A ). We confirmed these data using platelets from WT and GluR6 Ϫ/Ϫ mice. WT and KO platelets express equal total p38 by Western blot ( Figure 4B) , and platelets were incubated with buffer or KA.
KA induced an increase in WT platelet P-p38, but KA had no effect on GluR6 Ϫ/Ϫ platelet P-p38 ( Figure 4C ).
Although the downstream signaling effects of MAPK pathways are sustained, the actual phosphorylation of p38 is often transient. To determine the time course of KAR signaling-induced platelet P-p38, we incubated platelets with KA as above, and P-p38 was determined at multiple time points. Similar to TbxB2 production, we found that P-p38 peaked at 10 minutes post KA addition ( Figure 4D ). This is a transient event, as P-p38 declined to baseline levels by 20 minutes post KA addition ( Figure 4D ), confirmed by Western blot (supplemental Figure VI) .
To place p38 in the KAR-induced COX activation pathway we incubated platelets with the p38 inhibitor SB203580 before the addition of KA. The KAR antagonist UBP302 was used to pretreat samples before the addition of KA as a negative control. As expected KA increased platelet thromboxane production ( Figure 4E , black versus white bars). This was blocked by preincubation of platelets with the p38 inhibitor ( Figure 4E , black versus light gray bars), implicating KAR induced P-p38 as a mechanism to increase platelet COX activation. KAR signaling also induced phosphorylation of ERK1/2 (supplemental Figure VII) , but ERK inhibition did not block KA induced thromboxane production (supplemental Figure VIII) .
Taken together, these data demonstrate that KAR signaling drives low-level thromboxane production in a manner dependent on p38 MAPK pathway activation. The induction of MAPK activation may in part account for glutamate mediated increase in agonist induced platelet activation by "priming" signaling pathways, thereby amplifying agonist induced ac- tivation. This is analogous to what has been noted in other important platelet signaling pathways; for example native low-density lipoprotein is known to sensitize platelets to other agonists in a manner that also involves MAPK. 27, 28 
KAR Signaling Is a Mediator of Platelet Function In Vivo
It is often difficult to extrapolate in vitro platelet function tests to the in vivo relevance of a particular platelet signaling pathway. To address this we used an intravital microscopy model of arterial thrombosis with WT and GluR6 Ϫ/Ϫ mice in which mesenteric arterioles were damaged with ferric chloride and the time to vessel occlusion determined by visualizing fluorescently labeled platelets ( Figure 5A ). WT mice on average form occlusive thrombi 500 seconds after vessel damage ( Figure 5B) . The time to vessel occlusion in GluR6 Ϫ/Ϫ mice is approximately twice as long as WT mice ( Figure 5B ). To investigate whether KAR antagonists may have antithrombotic therapeutic potential, mice were injected intravenous with control buffer or the KAR antagonist UBP302 and bleeding time determined after amputating the distal 3 mm of the tail. We also determined the time to vessel occlusion using the intravital microscopy mesenteric thrombosis model. Mice treated with KAR antagonists have prolonged bleeding time ( Figure 5C ) and prolonged time to mesenteric arteriole occlusion following ferric chloride damage ( Figure 5D ). These data show that the KAR modulates thrombosis in vivo.
Gene Variants in KAR Subunits Modify Platelet Response to Aspirin Treatment
Laboratory experiments evaluating GluR5 (GRIK1) and GluR6 (GRIK2) expression and function were followed by gene association studies in humans. Using an established cohort of whites and blacks, we examined the association of single nucleotide polymorphisms (SNPs) in the GluR5 (located on chromosome 21q22.11) and GluR6 (located on chromosome 6q16.3-q21) genes, with platelet function after aspirin treatment. A block of highly correlated SNPs in intron 1 of GluR5 was associated with urinary excretion of 11dehydro thromboxane B2 (Tx-M) in whites. Several of these SNPs were associated with platelet aggregation in blacks (Table, A, top). Significant associations were also observed after adjustments were made for baseline platelet function (for RS465566, Pϭ3.5ϫ10 Ϫ5 for Tx-M in whites, and Pϭ0.004 for collagen aggregation in blacks). Similar trends were observed for platelet aggregation in whites and Tx-M in blacks. The clinical relevance of these phenotypes is underscored by the fact that these measures are associated with greater risk of myocardial infarction (MI), stroke, and cardiovascular death in aspirin-treated patients with coronary artery disease (CAD). 29 -31 The adenine allele of a representative SNP in GluR5, rs465566, was associated with less residual platelet function after exposure to aspirin (ie, greater aspirin inhibition) for aggregation and Tx-M excretion (Table, B). A SNP in intron 13 of GluR6 was also associated with Tx-M in whites, but we were unable to reinforce this by finding an association in blacks (Table, A, bottom) . Taken together, these data identify polymorphisms in KAR that are associated with important changes in platelet function.
Discussion
Our work demonstrates that platelets express functional KARs that have an important role in platelet activation and thrombosis. We have now defined a pathway in which glutamate released from activated platelets binds to KAR, driving MAPK pathway activation and thromboxane production. Mice lacking KAR subunits no longer respond to KA and exhibit delayed thrombus formation after vascular injury. Furthermore, we have identified polymorphisms in KAR that are associated with changes in platelet function, validating the potential physiological relevance of the KAR and platelet glutamate signaling pathways in human health and disease. Glutamate has an important role in helping drive thrombus formation. Although glutamate does not directly increase the surface expression of markers of platelet activation such as P-selectin and active GPIIb/IIIa, it has a key function in amplifying the effects of agonist stimulation on platelet activation and aggregation. This and our previous studies demonstrate that glutamate receptor signaling makes thrombus formation more efficient in vivo. Mice lacking AMPAR or KAR subunits still form occlusive thrombi; however, it is significantly delayed. The function of glutamate in platelet activation can be seen as analogous to a rheostat in regulating the outcome of platelet agonist stimulation. Glutamate receptor signaling may in part serve to alter the "set point" for stimulation by other platelet agonists and thus augment and amplify platelet responses during thrombus generation. This is an important concept when considering that many of the important steps in platelet aggregation take place in close contact between platelets as a thrombus develops. The local increase in glutamate concentration as platelet activation proceeds serves to make other agonists such as thromboxane, thrombin, and ADP more effective. This may also help to focus thrombus generation locally to the site of vascular injury and lesion development.
One important downstream signaling event of KAR in platelets that may be important in reducing the set point to subsequent agonist stimulation is the production of low, subactivation threshold levels of thromboxane that on its own is not sufficient to increase measureable phenotypic markers of platelet activation. Rather, this low level p38 dependent thromboxane production makes platelets more sensitive to subsequent stimuli, thus amplifying agonist response and making thrombus formation more efficient. This is similar to previous descriptions of other important platelet signaling pathways. For example, native low-density lipoprotein is known to sensitize platelets to other agonists in a manner that also involves MAPK. Serotonin, a small neurotransmitter similar to glutamate, is best understood in neurobiology. Serotonin also has little direct platelet stimulatory effects but can increase platelet response to other agonists in ways that are only beginning to be appreciated. 3, 11, 32, 33 Platelets have many activation pathways that become integrated during thrombus generation. Hemostasis is vital to survival, likely leading to evolutionary pressures resulting in redundant activation signaling pathways. Ensuring that thrombosis is efficient and localized is advantageous, and this is accomplished through the elaboration of activation molecules within the developing thrombus (such as glutamate) that help to sustain and amplify platelet activation and thrombus formation in a localized manner. These messenger molecules and signaling pathways provide attractive targets for platelet directed antithrombotic therapies. Acute vascular thrombosis is the major pathophysiologic process underlying acute myocardial infarctions and ischemic strokes. Antiplatelet therapies have been cornerstones of the medical armamentarium in acute coronary syndromes, cerebrovascular accidents, and now coronary stent thrombosis and restenosis. The ideal antithrombotic and antiplatelet agent should inhibit pathological platelet aggregation while minimizing the risk of bleeding. Our results indicate that glutamate signaling pathways may provide such a therapeutic target. Because glutamate is not a "traditional" platelet agonist and serves primarily to amplify agonist-induced platelet response, mice lacking glutamate receptor subunits do not exhibit spontaneous bleeding or hemorrhagic phenotypes. Rather, thrombus formation in mice treated with glutamate receptor antagonists and mice lacking glutamate receptor subunits is left intact, although it is delayed and less efficient. Our mouse bleeding time studies with a KAR inhibitor however indicate that any potential use of these compounds in humans would have to be approached with caution to prevent adverse bleeding events. We do not yet fully appreciate the pharmacokinetics of these compounds. Nonetheless, glutamate antagonists make an attractive potential adjunctive therapy in the treatment of patients with acute coronary syndromes and strokes that warrants further consideration and study.
Our results have consistently demonstrated that glutamate amplifies platelet activation via the AMPAR and KARs, but acute NMDAR signaling has little effect on platelet activation. A major difference in these types of ionotropic glutamate receptors is that the KAR and AMPAR both mediate the influx of sodium whereas the NMDAR forms primarily a calcium permeable channel. Calcium signaling is obviously very important in platelet activation; however, there are multiple other pathways that provide for calcium influx during platelet activation thus blocking or triggering the NMDAR may not exert a significant effect on platelet activation. There are limited cellular mechanisms to rapidly depolarize platelet membranes, underscoring the notion that glutamate signaling through the KAR and AMPAR may have relatively greater effect on platelet activation in acute settings. This does not rule out the possibility that the NMDAR is important in other aspects of platelet biology. NMDAR has been shown to have a role in regulating platelet production and megakaryopoesis 9 and in the brain NMDAR signaling can also alter AMPAR and KAR densities and function. It is possible that because the effects we are observing are very acute, NMDAR has other important platelet functions that are unappreciated due to the constraints of our ex vivo and in vivo systems.
We examined the relationship between SNPs in 2 gene components of the human KAR (subunits GluR5 and GluR6) and platelet functional responses to aspirin. The goal of this analysis was to determine whether gene variants in components of human KAR have clinically relevant platelet functional phenotypes (such as in this case, aspirin response). These data demonstrated that there are important SNPs in KAR subunits that result in variability in aspirin response, a clinically defined and poorly understood phenomenon. Significant SNPs were approximately replicated in each ethnic group examined, adding great significance of the results. Mechanistic insight into how the block of SNPs, in GluR5 in particular, results in this interesting phenotypic change in platelet function is not within the scope of this initial description of the role of KAR in platelet activation and thrombus formation, but the data does lend itself to speculation for future study. The variant allele block (minor allele) is associated with less platelet aggregation and urinary thromboxane metabolite post aspirin in both whites and blacks. These data imply that the allelic variant confers greater aspirin induced suppression of platelet activation. Aspirin effectively blunts COX activity and our results define a KAR-mediated signaling pathway that augments platelet activation in part through COX stimulation. Does this mean that a reduction in KAR signaling in these individuals results in the loss of the KAR signaling pathway that leads to COX activation, thereby conferring greater platelet aspirin sensitivity? Does this imply an alternative pathway in COX stimulation through KAR in platelets that is yet to be understood? At this time any answer is purely speculative and will require further investigation. However, the importance of the genetic data are to demonstrate for the first time the functional and clinical relevance of glutamate receptor signaling in a large well described cohort. It should also be emphasized that because regulation of thrombosis is so critical, platelets have many redundant signaling pathways. Phenotypes in human populations where genes and protein products are not totally disrupted are often only noted under physiological stress or pharmacological treatment response. These data may emphasize this principal.
Platelet glutamate receptor signaling is an exciting and relatively unexplored area of platelet biology. Our data indicate it may have a significant role in platelet function that impacts vascular disease pathogenesis. Although much work remains to be done to fully validate the importance of the platelet glutamate receptor pathway, our study advances our current understanding of the novel role of glutamate receptors in platelet biology and in potential contribution to the variabilities in response to antiplatelet therapy. 
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